Cingulate (NASDAQ:CING) Research Coverage Started at Roth Mkm

Roth Mkm began coverage on shares of Cingulate (NASDAQ:CING) in a report published on Friday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $12.00 price objective on the stock.

Separately, Maxim Group upgraded Cingulate from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th.

Cingulate Price Performance

CING opened at $4.81 on Friday. Cingulate has a 52-week low of $1.80 and a 52-week high of $88.44. The business’s fifty day moving average is $4.36 and its 200-day moving average is $4.15.

Cingulate (NASDAQ:CING) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.22) by $0.39. On average, research analysts expect that Cingulate will post -9.26 earnings per share for the current year.

Hedge Funds Weigh In On Cingulate

A hedge fund recently bought a new stake in Cingulate stock. Jane Street Group LLC bought a new position in shares of Cingulate Inc. (NASDAQ:CING) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 21,031 shares of the company’s stock, valued at approximately $106,000. Jane Street Group LLC owned 0.66% of Cingulate at the end of the most recent quarter. 41.31% of the stock is owned by institutional investors and hedge funds.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.